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Abstract
Background: Infections may be associated with exacerbation of allergic and autoimmune diseases. Paradoxically,
epidemiological and experimental data have shown that some microorganisms can also prevent these pathologies. This
observation is at the origin of the hygiene hypothesis according to which the decline of infections in western countries is at
the origin of the increased incidence of both Th1-mediated autoimmune diseases and Th2-mediated allergic diseases over
the last decades. We have tested whether Toll-like receptor (TLR) stimulation can recapitulate the protective effect of
infectious agents on allergy and autoimmunity.
Methods and Findings: Here, we performed a systematic study of the disease-modifying effects of a set of natural or
synthetic TLR agonists using two experimental models, ovalbumin (OVA)-induced asthma and spontaneous autoimmune
diabetes, presenting the same genetic background of the non obese diabetic mouse (NOD) that is highly susceptible to
both pathologies. In the same models, we also investigated the effect of probiotics. Additionally, we examined the effect of
the genetic invalidation of MyD88 on the development of allergic asthma and spontaneous diabetes. We demonstrate that
multiple TLR agonists prevent from both allergy and autoimmunity when administered parenterally. Probiotics which
stimulate TLRs also protect from these two diseases. The physiological relevance of these findings is further suggested by
the major acceleration of OVA-induced asthma in MyD88 invalidated mice. Our results strongly indicate that the TLR-
mediated effects involve immunoregulatory cytokines such as interleukin (IL)-10 and transforming growth factor (TGF)-b
and different subsets of regulatory T cells, notably CD4
+CD25
+FoxP3
+ T cells for TLR4 agonists and NKT cells for TLR3
agonists.
Conclusions/Significance: These observations demonstrate that systemic administration of TLR ligands can suppress both
allergic and autoimmune responses. They provide a plausible explanation for the hygiene hypothesis. They also open new
therapeutic perspectives for the prevention of these pathologies.
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Introduction
There is compelling evidence to indicate a central role of Toll-
like receptors (TLRs) in the stimulation of innate and adaptive
immunity when applied at the site of immune responses [1–3].
More limited but convincing observations suggest a possible role
of TLRs in the triggering of allergic and autoimmune diseases
[4–9]: such induction could not be obtained in several
experimental models after genetic invalidation of certain TLRs
or one of their adaptor molecules, namely MyD88 [6,7,10,11].
On the other hand, more unexpected observations have indicated
that systemic TLR stimulation can prevent the onset of allergic
and autoimmune diseases when it is implemented early enough in
the natural history of the disease. Thus, administration of the
TLR4 agonist LPS and of the TLR9 agonist CpG has been
shown to prevent spontaneous diabetes onset in the non obese
diabetic (NOD) mouse [12,13]. Similarly, administration of
various TLR agonists may prevent onset of ovalbumin (OVA)-
induced allergic asthma in various mouse strains including
BALB/c and A/J mice [14–20], even though the same agonists
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11484may exceptionally show the opposite effect depending on the
experimental conditions [21–24].
TLR-mediated prevention of allergic and autoimmune diseases
could represent one of the major mechanisms underlying the
hygiene hypothesis according to which the major increase of these
diseases observed in western countries over the last three decades
is secondary to the decline of infections [25–27]. Originally
elaborated in the context of an increased susceptibility to allergy
we proposed back in 2002 that the hypothesis could also apply to
autoimmune diseases [28]. Validating the hygiene hypothesis in
the clinical setting is a complex issue. A major problem is that
some particular infections may trigger/exacerbate either allergic
or autoimmune diseases and that the nature of the infections
contributing to protection is still ill-defined. This is why so far the
best direct evidence in support of the hygiene hypothesis has been
collected from experimental animal models such as the NOD
mouse in which a variety of pathogens (living pathogens or
bacterial extracts) totally prevent autoimmune diabetes onset
[29–32] (reviewed in [28]). The study of bacterial extracts, which
are easier to use and analyze as compared to living pathogens, is
complicated by the multiplicity of their components.
When reports on the hygiene hypothesis were confined to
allergic diseases the Th1/Th2 paradigm was proposed as a leading
mechanism to explain the effect observed. Thus, given the
reciprocal down-regulation of Th1 and Th2 cells some authors
initially suggested that, in developed countries, the lack of
microbial burden in early childhood which normally favors a
strong Th1-biased immunity would redirect the immune response
towards a Th2 phenotype and, therefore, predispose the host to
allergic disorders. Such conclusions were challenged once the
hygiene hypothesis was extended to autoimmunity as Th1
responses in the case of autoimmunity are not protective but
pathogenic [28].
Taking into account these considerations we chose to study the
effect of TLR stimulation in the NOD mouse that is an
experimental model where development of allergy and spontane-
ous autoimmunity can be studied in parallel in the context of an
identical genetic background. In fact, NOD mice represent a
particularly appropriate model since, in addition to their well
documented susceptibility to develop spontaneous autoimmune
diabetes [33,34], they have been shown to be a strain that is highly
susceptible to the induction of allergic asthma [35]. It was our
rationale that this approach would provide us with the opportunity
to test whether common regulatory immune mechanisms, possibly
involving TLR stimulation, exist underlying infection-mediated
protection against both allergy and autoimmunity namely,
whether these common regulatory immune mechanisms control
both Th1 and Th2 responses.
Thus, one may postulate that TLR ligands that are present in
numerous pathogens have a general non specific inhibitory effect
on allergic and autoimmune responses.
Here, we have tested whether TLR stimulation can recapitulate
the protective effect of infectious agents on allergy and
autoimmunity. To that aim we first performed a systematic
screening of a set of natural or synthetic TLR agonists in two
experimental models, OVA-induced asthma and autoimmune
diabetes. Secondly, in the same models we investigated the effect
of probiotics. We also examined the effect of the genetic
invalidation of MyD88 on the development of spontaneous
diabetes, as previously performed by the group of A. Chervonsky
[36] and additionally in the allergic asthma model.
Collectively, results presented in this study demonstrate that
systemic TLR stimulation by both probiotics and TLR agonists is
efficacious in preventing from both allergy and autoimmunity.
Materials and Methods
Mice
Conventional NOD mice (K
d, I-A
g7, and D
b) were bred in our
animal facility at the Ho ˆpital Necker as well as CD28
2/2NOD
mice (a kind gift from J.A. Bluestone, UCSF, San Francisco, CA),
CD1d
2/2NOD mice (a kind gift from M. Kronenberg, La Jolla
institute, San Diego, CA) and IL-4
2/2NOD mice (a kind gift from
D. Mathis and C. Benoist, Josslin Center, Boston, MA). We
backcrossed MyD88
2/2C57BL/6 mice into the NOD genetic
background (N13). Seven-week-old female C57BL/6 mice were
purchased from Janvier.
Ethics Statement
All experiments have been conducted in accordance with
European Union Council Directives (86/609/EEC) and with
institutional guidelines (INSERM: Institut National de la Sante ´e t
de la Recherche Me ´dicale). The animal facility has an agreement
delivered by the Prefecture de Police of Paris, France.
TLR agonists and probiotics
The P40 protein of Klebsiella pneumoniae was purified as
previously described [37]. We obtained purified lipopolysaccha-
ride (LPS) from S. minnesota and R848 (resiquimod) from Alexis
Biochemicals (Paris, France). Polyinosinic-polycytidylic acid
(Poly(I:C)) was purchased from Invivogen (Toulouse, France)
and Sigma-Aldrich (St Louis, MO) as well as lipid A from S.
Minnesota. Pam3Cys: S-[2,3-bis(palmitoyloxy)-(2-RS)-propyl]-N-
palmitoyl-(R)-Cys-(S)-Ser-Lys4-OH from Invivogen. The probiotic
preparation VSL#3 containing bifidobacterium, lactobacillium and
streptococcus was purchased from Sigma-tau (Ivry-sur-Seine,
France).
The ovalbumin-induced airway inflammation model and
treatments
On day 0 NOD mice were sensitized with 100 mg of chicken egg
OVA (Sigma-Aldrich) in 1.6 mg aluminium hydroxide i.p. in a
volume of 200 ml. Then they were challenged with 50 mg/ml
OVA upon aerosol exposure on three consecutive days (days 7–9)
to induce allergic airway inflammation. Controls received a NaCl
solution. The TLR agonists P40, Poly(I:C), LPS or R848 were
injected i.p. 24 hrs and 1 hr before the first challenge.
We assessed lung function using two different methods. The first
was non-invasive barometric plethysmography and consisted in
measuring airway hyper-responsiveness (AHR) 24 hrs after the last
OVA challenge by delivering an aerosol of methacholine (Mch)
(Sigma-Aldrich) for 1 min at 150 mM to mice placed in a
plethysmographic chamber (EMKA technologies, Paris, France).
The index of airflow obstruction was expressed as enhanced pause
(Penh). In some experiments airway resistance and compliance
were measured with the FlexiVent device (FlexiVent; SCIREQ,
Montreal, Que ´bec, Canada). Twenty four hours after the last
challenge, airway resistance (R) and compliance (C) to methacho-
line were measured. Mice were anesthetized with an intraperito-
neal injection of sodium pentobarbital (70 mg/kg). The trachea
was exposed, a tracheotomy was performed to insert a 18-gauge
needle connected to a computer-controlled small-animal ventila-
tor. Mice were quasi-sinusoidally ventilated with a tidal volume of
10 ml/kg at a frequency of 150 breaths/min and a positive end-
respiratory pressure of 2 cmH2O to achieve a mean lung volume
close to that during spontaneous breathing. After recording
baseline values, each mouse was challenged with an aerosol of
methacholine, generated with an in-line nebulizer and adminis-
tered directly through the ventilator for 5 seconds delivering
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R and C were measured with a ‘‘snapshot’’ protocol each 20
seconds for 2 min. The mean of these six values was deduced for
each methacholine concentration. For each mouse, R and C were
plotted against methacholine concentration (from 0 to 10 mg/ml),
as previously described [38].
It is relevant to mention that in our colony NOD mice develop
spontaneous insulin-dependent diabetes as assessed by hypergly-
cemia and glycosuria by 12–13 weeks of age. Before this point in
time all animals exhibit normal glucose levels. As done in other
strains OVA sensitization was performed in 8 week-old mice and
given the kinetics of the experiment (described above) the
challenge was performed one week later (day 7 to 9). Therefore
experiments were completed when NOD mice were 9–10 week
old which explains that we never observed abnormal glucose levels
in NOD mice undergoing OVA sensitization/challenge.
For probiotic treatment, VSL#3 preparation (5. 10
9 bacteria/
mouse in 100 ml PBS) was administered by gavage 5 days a week
during 6 weeks before the OVA immunization. In these
experiments control mice were treated with PBS.
An infraoptimal protocol was also set for MyD88
+/+ and
MyD88
2/2 NOD mice. Here mice were immunized with only
50 mg of OVA in 1.6 mg of aluminium hydroxide and challenged
by aerosol exposure with a single reduced dose of OVA (20 mg/ml)
on day 7. Samples were collected 48 hrs after the challenge for
further analyses.
In some experiments a monoclonal antibody specific for the IL-
10 receptor, that neutralizes IL-10 activity (1B1.2) was adminis-
tered i.p. 48 hrs and 1 hr before the first challenge.
For adoptive transfer experiments, 5610
6 CD4
+ cells were purified
from total spleen cells following magnetic bead sorting (Myltenyi
B i o t e c ,P a r i s ,F r a n c e )r e c o v e r e df rom either probiotic-treated or
untreated control NOD mice. The cells were injected i.v. to syngeneic
recipients that had already been immunized with OVA and which
received the CD4
+ cell infusion 1 hr before the first challenge.
Bronchoalveolar lavage
Mice were euthanized with urethane (Sigma-Aldrich) adminis-
tered i.p. The lungs were cannulated through the trachea to
perform the BALF. Cellular fractions were recovered and
processed for differential staining by cytospin centrigugation.
The BALF as well as lung homogenates were analyzed for cytokine
and chemokine content by ELISA (R&D Systems, Lille France)
according to manufacturers’ specifications.
Monitoring for autoimmune diabetes and treatment of
NOD mice
We treated NOD mice with TLR agonists or PBS and monitored
weekly for clinical signs of diabetes using Gluko-Test reagent sticks, to
detect glucose in urine samples (Boehringer Mannheim, Meylan,
France). When needed, glycemia was also measured in a drop of blood
collected from the tail vein and using a Reflolux S glucometer
(Boehringer Mannheim). Incidence of diabetes was defined based on
the discovery, upon serial monitoring, of glycosuria and hyperglycemia
(fasting glycemia .2.5 g/L).
NOD mice were also treated with probiotics (VSL#3; 5.10
9
bacteria/mouse in 100 ml PBS) delivered orally by gavage 5 times
a week starting at 4 weeks of age. In these experiments control
mice received PBS.
Histological analysis
Pancreas were collected when needed, fixed in 4% formalde-
hyde and paraffin-embedded. Serial 5-mm sections were stained
with hematoxylin and eosin. Mononuclear cell infiltration was
scored by counting at least 100 independent islets/recovered
pancreas and distinguishing three distinct patterns that were: 1)
Intact islets: islets showing a normal morphology and total absence
of infiltrating mononuclear cells, 2) Peri-insulitis: islets showing a
generally preserved morphology but presenting a significant
number of mononuclear cells that remain confined to the
periphery of the islets and 3) Destructive insulitis: islets showing
a disrupted morphology and a significant number of invading
mononuclear cells.
In vitro cultures
For cytokine production 2610
5 splenocytes from MyD88
+/+
and MyD88
2/2 C57BL/6 mice were cultured in complete
medium: RPMI supplemented with antibiotics and 10% fetal calf
serum (Invitrogen, Cergy-Pontoise, France) in the absence or
presence of TLR agonists at varying doses. After 48 (for IL-10) to
72 (for TGF-b) hrs of culture at 37uC, supernatants were
harvested. For TGF-b, responses to TLR agonists were compared
to control cultures performed in serum-free medium. When
needed peritoneal macrophages were collected 48 hrs following
i.p. injection with 2 ml of thioglycollate broth (BioMe ´rieux,
Craponne, France). Macrophages were then cultured in presence
of probiotics for 24 hrs at 37uC. All supernatants were harvested
and stored at 280uC until cytokines were dosed by ELISA (R&D
systems, Lille, France).
Circulating cytokine analysis
NOD mice were injected with TLRs agonists or fed with
probiotics for two weeks (see details in the results section). Twenty
four hrs after the end of treatment, serum samples were collected
and levels of circulating TGF-b and IL-10 were measured by
ELISA (R&D systems).
Flow cytometry analysis
Spleen cells were recovered following treatment with TLR
agonists or probiotics (see details in the results section). Cell
suspensions were stained with antibodies to CD25 (labeled to
phycoerythrin (PE)) and CD4 (labelled to phycoerythrin fluores-
cein isothiocyanate (FITC)) (BD Biosciences, Pont de Claix,
France). Then cells were fixed and labelled with the Foxp3 kit (BD
Biosciences) according to manufacturer’s instructions. Samples
were collected on a FACSCantoII cytometer (BD Biosciences).
Data were gated on mononuclear cells with forward- and side-
scatter properties using the FACS Diva Software.
Statistical analysis
Diabetes incidence was plotted using the Kaplan-Meier method,
i.e., nonparametric cumulative survival plot. Statistical comparison
between curves was performed using the logrank (Mantel-Cox) test
that provided the corresponding x
2 values. When needed, statistical
comparison of mean values was performed using Student’s t test. In
the allergic model, the difference between groups was calculated
with the Mann-Whitney U test for unpaired data (GraphPad Prism
Software, La Jolla, CA). Differences were considered significant
when P,0.05 (* P,0.05, ** P,0.01, *** P,0.005).
Results
Effect of TLR agonists on allergic asthma and
autoimmune diabetes in NOD mice
We tested the effect of agonists of TLR2 (P40 protein of Klebsiella
pneumoniae and the Pam3Cys lipopeptide), TLR3 (double-stranded
TLR and the Hygiene Hypothesis
PLoS ONE | www.plosone.org 3 July 2010 | Volume 5 | Issue 7 | e11484Figure 1. Stimulation of TLR pathways prevents allergic inflammation and airway hyper-responsiveness. NOD mice were treated as
described in the Methods section. Briefly, mice immunized with OVA on day 0 were challenged with OVA or NaCl (controls) on days 7, 8 and 9. Each
TLR agonist or phosphate-buffered saline (PBS) was administered 24 hrs and 1 hr before the first challenge. OVA-challenged mice were treated with
TLR and the Hygiene Hypothesis
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experimental allergic asthma and autoimmune diabetes in the
NOD mouse. In the asthma model, NOD mice were immunized
intraperitoneally on day 0 with OVA in presence of alum,
challenged one week later with 3 consecutive OVA aerosol
administrations and analyzed 24 hrs after the last challenge.
Following this protocol, mice presented allergic inflammation and
abnormal lung function. Allergic inflammation resulted in an
increase of cell recruitment including eosinophils in the BALF, and
of cytokine and chemokine production, IL-4 and eotaxin
respectively, in the lung. Lung function was assessed by measuring
AHR using non-invasive whole-body plethysmography (Figure 1)
and also in some experiments by measuring airway resistance (R)
and compliance (C) using an invasive method (Figure 2).
The TLR2, TLR3, TLR4 and TLR7 agonists were adminis-
tered 24 hrs and 1 hr before the first challenge. In treated mice a
significant decrease in AHR as well as in eosinophil counts in
BALF and levels of IL-4 and eotaxin in the lung were observed
(Figure 1). Levels of IL-5, IL-13, IL-17 and TARC in the lungs
were also decreased (data not shown). As measurement of AHR
using non-invasive plethysmography may be subject biases (linked
to changes in mice breathing patterns) we validated our results, in
the case of mice treated with the TLR7 agonist (R848) by
measuring airway resistance and compliance using a FlexiVent
device. As detailed in Figure 2, R848 administration resulted in
significantly decreased lung resistance and compliance which
confirmed the AHR values previously described (Figure 1).
In the spontaneous autoimmune diabetes model, TLR agonists
were injected once a week intraperitoneally (i.p.) starting at four
weeks of age for 20 consecutive weeks. In these conditions, most of
the TLR agonists tested were protective (Figure 3A). It is
interesting that, for a given TLR, some agonists were not
protective although their efficiency at stimulating the TLR
pathway in vitro has been well demonstrated. Thus, lipid A, which
is the lipid portion of LPS, was not protective whereas LPS was
(Figure 3A). Most agonists required a long treatment (20
consecutive weeks) for inducing protection, with the exception of
P40 which was also protective after a shorter 10-week treatment
(Figure 3B). TLR agonists were protective when treatment was
started early in disease development, between 4 and 10 weeks of
age. A delayed treatment did no longer protect from diabetes
(Figure 3C); disease aggravation was never observed.
In protected animals the histological analysis of pancreata showed
a reduction in destructive islet infiltration (i.e. invasive insulitis)
(Figure 4). It is important to mention here that up to three weeks of
ageuntreatedNODmicedonotshowanyisletinfiltrationorinsulitis.
The first infiltrating mononuclear cells appear by 3–4 weeks of age
and accumulate up to approximately 12 weeks of age under the form
of a non invasive peripheral insulitis (peri-insulitis, see Figure 4A). By
12 weeks of age the topography of the infiltration changes and the
insulitis becomes invasive and aggressive (invasive insulitis, see
Figure 4A). This form of insulitis is associated to active destruction
of insulin-secreting b-cells;this is the point in timewhere the first mice
showing overt hyperglycemia are observed. It appeared that
depending on the agonist the effect observed was either a global
prevention of the infiltration (in the case of P40) or a control of
insulitis progression (in the caseof LPS, R848 and Poly(I:C))withhigh
proportion of infiltrated islet showing a benign form of non invasive
peripheral insulitis (Figure 4). Results on the insulitis patterns in TLR
ligand-treated mice versus controls were recovered at the end of the
experiments when mice were all aged 25–27 weeks, a quite advanced
point in time in disease progression (by 13 weeks after diabetes and
invasive insulitis is detected in untreated controls).
Contrasted effects of MyD88 invalidation on allergic
asthma and autoimmune diabetes
In order to study if exogenous or endogenous pathogens
(intestinal commensal bacteria) modulate OVA-induced allergic
PBS or (A) P40 (200 mg/challenge/mouse), a TLR2 agonist, (B) Poly(I:C) (100 mg/challenge/mouse), a TLR3 agonist, (C) LPS (100 mg/challenge/mouse),
a TLR4 agonist and (D) R848 (100 mg/challenge/mouse), a TLR7 agonist. AHR to Mch was measured 24 hrs after the last challenge and total cell as
well as eosinophils in BALF and cytokine and chemokine concentrations in lungs. Mice treated with TLR agonists showed a decreased AHR,
eosinophilia and IL-4 and eotaxin production as compared to control mice (* p,0.05; ** p,0.01). These experiments were performed twice using 4 to
6 mice per group. One representative experiment is shown.
doi:10.1371/journal.pone.0011484.g001
Figure 2. Treatment with the TLR7 agonist R848 prevents airway resistance and compliance. NOD mice immunized with OVA were
injected with R848 and challenged with OVA as described in the methods section. Lung resistance (R) and compliance (C) were measured 24 hrs after
the last aerosol challenge with OVA or NaCl. Results are representative of one experiment out of 2 performed using 4 to 6 mice per group.
doi:10.1371/journal.pone.0011484.g002
TLR and the Hygiene Hypothesis
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these diseases. At variance with results described above which
showed a striking parallelism in the pharmacological effects of the
TLR agonists in both conditions, impact of MyD88 deficiency on
asthma and diabetes was strikingly different. Thus, MyD88
2/2NOD
mice immunized with OVA died (with asphyxia) within few hours
following the first or the second aerosol challenge with OVA as
compared to wild-type MyD88 sufficient NOD mice which
regularly survived the three challenges (Figure 5A). Given these
results MyD88
2/2NOD mice were immunized and challenged
with lower doses of OVA (50 mg as compared to 100 mg for
immunization and 20 mg/ml as compared to 50 mg/ml for
challenge) to allow a significant mouse survival. Results shown on
Figure 5B indicate that following this infraoptimal OVAstimulation
BALF from MyD88
2/2 mice contained significantly increased
numbers of total leucocytes and eosinophils as compared to
controls.
Contrasting with the exacerbated airway allergic response the
incidence of autoimmune diabetes was drastically reduced in
MyD88
2/2NOD mice (Figure 5C). None of these mice developed
Figure 3. Stimulation of TLR pathways prevents spontaneous autoimmune diabetes in NOD mice. A. Female NOD mice were injected
i.p. with 200 mg P40, 100 mg Poly(I:C), 5 mg LPS from S. minnesota,5mg Lipid A, 10 mg R848 or PBS once a week, starting at 3–4 weeks of age and for
20 consecutive weeks. Mice were monitored weekly for the advent of glycosuria. Significant prevention from diabetes was observed with most TLR
agonists tested (* p,0.05; ** p,0.01) but not with Lipid A. Each panel represents one of 3 independent experiments using 8 mice per group. B. A
shorter treatment with the TLR2 agonist P40 administered between 4 and 14 weeks also induced significant protection from diabetes (** p,0.01). C.
Treatment with Poly(I:C) was highly protective if started up to 10 weeks of age but not later (at 16 weeks of age).
doi:10.1371/journal.pone.0011484.g003
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insulitis was also observed (Figure 5D).
Effect of TLR agonists on immune regulatory pathways
Using both in vitro and in vivo models we investigated the
implication of immune regulatory cytokines and of subsets of
regulatory lymphocytes in the protective effect of TLR2, TLR3,
TLR4 and TLR7 agonists.
In vitro, the 4 agonists induced the production of either TGF-b
(for P40, Poly(I:C) and LPS) or IL-10 (all 4 agonists) by spleen cells
(Figure 6A). In vivo, serum concentrations of TGF-b andIL-10 were
measured 24 hrs after the agonists’ injection. As shown in
Figure 6B, an increased level of IL-10 and TGF-b was observed
after treatment with TLR2, 3 or 7 agonists. We also observed that
the administration of a single dose of LPS or R848 increased the
number of regulatory CD4
+CD25
+Foxp3
+ T cells in the spleen
24 hrs after injection whereas Poly(I:C) did not (Figure 7 and data
not shown).
To directly evaluate in vivo the role of CD4
+CD25
+Foxp3
+ and
NKT cells in the protection induced by TLR3 and TLR4 agonists
we took advantage of CD28
2/2 and CD1d
2/2NOD mice that
are deficient in these two subsets respectively. Results shown in
Figure 6C demonstrated that the protective effect of LPS was
not observed in CD28
2/2NOD mice but was still present in
CD1d
2/2NOD mice. Conversely, the protective effect of
Poly(I:C) was observed in CD28
2/2 NOD mice but not in
Figure 4. Histological analysis of pancreas. A. Representative photomicrographs of distinct patterns observed in pancreas sections. Histological
examination of hematoxylin and eosin stained pancreas sections recovered from the various experimental groups was performed (n=8 per group).
Islet infiltration (insulitis) was scored by deducing the proportion of non-infiltrated islets (healthy islets) and of islets showing a non destructive
peripheral insulitis (peri-insulitis) or an invasive/destructive insulitis (destructive insulitis). B. The relative degree of islet inflammation in mice treated
with P40, Poly(I:C), LPS or R848 is shown in a cumulative histogram as compared to PBS-treated controls.
doi:10.1371/journal.pone.0011484.g004
TLR and the Hygiene Hypothesis
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2/2 NOD mice. Interestingly, the TLR3 agonist-mediated
protection that was dependent on the presence of NKT cells was
abrogated in IL-4
2/2 NOD mice which was not the case for the
protective effect of LPS, whose protective effect did not depend on
NKT cells (Figure 6C).
Effect of probiotic bacteria on allergic asthma and
autoimmune diabetes
We studied the capacity of probiotic bacteria to protect from
both experimental allergic asthma and autoimmune diabetes.
In the allergic asthma model we administered VSL#3, a
commercial combination of probiotic bacteria (bifidobacterium,
lactobacillium and streptococcus), orally for 6 weeks before the first
i.p. OVA immunization. In the spontaneous diabetes model,
treatment was given once a week for 20 consecutive weeks starting
at 4 weeks of age. Results demonstrated significant protection in
the two models (Figure 8A,B). The protective effect was dose-
dependent (data not shown).
In vitro, the same probiotic preparation induced Tumor Necrosis
Factor (TNF)- a and IL-10 production by macrophages, an effect that
was MyD88-dependent as shown by the absence of production of both
cytokines by cells obtained from MyD88
2/2 mice (Figure 8C).
The TLR dependency of the probiotic bacteria effect was
further confirmed in vivo in the allergic asthma model since
MyD88
2/2NOD mice were insensitive to treatment, using the low
OVA dose described above, compatible with mouse survival
(Figure 8D). In MyD88
2/2NOD mice results showed no effect of
probiotic bacteria treatment on either eosinophil recruitment or
IL-4 production (Figure 8D).
Interestingly, in the sera of mice protected following probiotic
bacteria administration increased levels of TGF-b were detected
(Figure 9A). We also detected in the spleen of protected mice an
increased frequency of CD4
+CD25
+FoxP3
+ T cells (Figure 7).
Figure 5. MyD88
2/2 NOD mice are sensitive to airway allergic inflammation but resistant to the development of autoimmune
diabetes. As compared to MyD88
+/+ NOD mice, MyD88
2/2 NOD mice were hypersensitive to experimental allergic asthma. A. The left panel shows
the data observed in MyD88
+/+ (n=25) and MyD88
2/2 (n=35) mice immunized with our conventional protocol, namely immunization with 100 mgo f
OVA on day 0 and challenge with 50 mg/ml of OVA or NaCl on days 7, 8 and 9. Results are expressed in percentage of survival. The right panel shows
the data observed when using an infraoptimal protocol according to which MyD88
+/+ (n=10) and MyD88
2/2 (n=15) mice were immunized with
50 mg of OVA on day 0 and challenged only once with 20 mg/ml of OVA or NaCl on day 7. Results are also expressed in percentage of survival. B.
Results show that, using the infraoptimal immunization and challenge protocol, the eosinophil recruitment in BALF was more important in MyD88
2/2
as compared to MyD88
+/+ mice (* p,0.05). C. Monitoring for the cumulative incidence of spontaneous diabetes showed that MyD88
2/2 NOD mice
(n=25) were fully protected from disease (littermate female MyD88
+/+ NOD mice (n=60) showed a normal disease incidence reaching 80% by 30
weeks of age) (** p,0.01). D. Histological examination of hematoxylin and eosin stained pancreas sections recovered from 20-week-old MyD88
+/+
and MyD88
2/2 NOD mice (n=8 per group) showed that a great majority of islets in MyD88
2/2NOD mice were insulitis free.
doi:10.1371/journal.pone.0011484.g005
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PLoS ONE | www.plosone.org 8 July 2010 | Volume 5 | Issue 7 | e11484Figure 6. Stimulation of the TLR/MyD88 pathway modulates immune regulatory cytokines and lymphocyte subsets. A. In vitro
stimulation of C57BL/6 mouse spleen cells with varying doses of different TLR agonists (P40, 1 or 20 mg/ml; Poly(I:C), 1 or 10 mg/ml; LPS, 0.1 or
1 mg/ml; R848 0.1 or 1 mg/ml) induced the production of cytokines such as IL-10 (at 48 hrs) and TGF-b (at 72 hrs). Study of splenocytes from MyD88
+/+
or MyD88
2/2 C57BL/6 mice confirmed that the effect is dependent on the MyD88 pathway. Results are expressed as mean cytokine level 6 SD.
Results are representative of three independent experiments. B. Circulating levels of IL-10 and TGF-b were detected following in vivo administration
of TLR agonists. NOD mice were injected i.p. with 20 mg of P40, 100 mg of Poly(I:C) or 10 mg of R848 (n=8 per group). Control mice were injected with
saline (PBS). Sera were collected 24 hours after the injection and cytokine levels were measured by ELISA (*p,0.05; ** p,0.01; *** p,0.005). C. The
same conventional treatment protocol (described in Figure 3) with the TLR4 agonist LPS (5 mg/week/mouse) and the TLR3 agonist Poly(I:C), that
protected wild type NOD mice from diabetes, was applied to female NOD mice invalidated for CD28 (CD28
2/2), CD1d (CD1d
2/2) and IL-4 (IL-4
2/2).
Results obtained showed that the Poly(I:C)-induced protective effect was maintained in CD28
2/2 NOD mice (*p,0.05) but not in CD1d
2/2 and
IL-4
2/2 NOD mice. As a mirror-like image the LPS-induced protective effect was maintained in CD1d
2/2 and IL-4
2/2 NOD mice (* p,0.05) but not in
CD28
2/2 NOD mice. One representative experiment out of 2 performed is shown.
doi:10.1371/journal.pone.0011484.g006
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effect of probiotic bacteria was IL-10-dependent. In fact,
administration of an anti-IL-10 receptor monoclonal antibody
before the first aerosol OVA challenge completely abolished the
therapeutic effect (Figure 9C).
Finally, the probiotic protective effect was transferable by T
cells. Adoptive transfer of CD4
+ splenocytes from probiotic-treated
mice into OVA-challenged wild-type NOD mice significantly
inhibited AHR (Figure 9D).
Discussion
Here we show that a wide spectrum of agonists for various
TLRs administered systematically inhibits both allergic and
autoimmune responses extending in a comprehensive fashion
previous isolated reports. These results are at variance with
observations made after using TLR agonists at the site of antigen
administration in normal and pathological conditions as discussed
in the introduction.
The study of MyD88
2/2NOD mice provided different results
in asthma and diabetes, which initially surprised us in view of the
similarity of the effects of all TLR agonists in the two
animal models. The acceleration of OVA-induced asthma in
MyD88
2/2NOD mice is in agreement with the pharmacological
effects of TLR agonists in this model, corroborating their
postulated mode of action and supporting the notion that
environmental infectious agents contribute to the modulation of
allergic reactions through TLR stimulation. It is important to
mention at this point that one should not restrict the discussion to
the MyD88 adaptor. Other important adaptor molecules have
been identified such as TRIF that is involved in TLR4 and TLR3
signaling [39] and which may impact in the effect we observed
following LPS and/or Poly (I:C) treatment remains to be determined.
These data are in keeping with the previous report showing that
MyD88
2/2C57BL/6 mice present a Th2 skewed balance with
increased IgE levels [40]. It was more difficult to explain the
complete prevention of diabetes observed in MyD88
2/2NOD
mice reported by Chervonsky and observed in our study [36]. The
first interpretation is that MyD88 is mandatory for diabetes
development. Another possibility is that MyD88 deficiency favors
a significant change in the composition of the commensal flora or
the development of infections that both inhibit diabetes onset
[36,41]. The second interpretation is supported by Chervonsky’s
data showing that specific pathogen-free (SPF) MyD88
2/2NOD
Figure 7. Treatment of NOD mice with TLR4 or TLR7 ligands or probiotics induces CD4
+CD25
+FoxP3
+ Tregs. Mice were injected i.p.
with 5 mg of LPS, 10 mg of R848 or treated orally with the VSL#3 probiotic preparation 5 days a week for 2 weeks (n=5 per group). Twenty four hrs
after the end of treatment spleen cells were recovered, stained with labeled antibodies specific for CD4, CD25 and FoxP3. Representative flow
cytometry plots representing proportions of CD4
+CD25
+ and CD25
+FoxP3
+ T cells (examined on gated CD4
+ cells) are shown. In addition, the
corresponding histograms showing the total proportions of FoxP3
+ T cells (within the CD4
+CD25
+ and CD4
+CD25
2 compartments) are detailed for
each experimental group. For the FoxP3 staining, the isotypic controls showed values ranging 0.02–0.09%.
doi:10.1371/journal.pone.0011484.g007
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free MyD88
2/2NOD mice show normal diabetes incidence [36].
It may be interesting to mention here that invalidation of the
CD28 gene also shows contrasting effects on diabetes and asthma
with acceleration of diabetes and reduction of asthma [42,43].
Finally, it appears that our results showing diabetes prevention
with TLR agonists provide further support for TLR involvement
in the control of the diabetogenic response in NOD mice.
Our results point to several non mutually exclusive mechanisms
underlying asthma and diabetes prevention by TLR agonists.
These include: 1) the production of immune regulatory cytokines
that was observed both in vitro and in vivo, 2) the involvement of
CD4
+CD25
+FoxP3
+ regulatory T cells indicated by the loss of
protection observed in CD28
2/2 NOD mice that are devoid of
CD4
+CD25
+T cells [44]. A word of caution is however needed
concerning CD28 invalidation as it may alter a number of other
immune parameters than the production/differentiation of
CD4
+CD25
+FoxP3
+ regulatory T cells and 3) the involvement
of NKT cells demonstrated by the absence of diabetes protection
in CD1d
2/2NOD mice that are deprived of NKT cells [45]. It is
interesting to speculate at this point that, independently form the
precise mechanism(s) mentioned above involved in the ‘induction’
phase of the TLR ligand therapeutic effect and which per se are not
antigen-specific, over long-term ‘maintenance’ of protection from
allergy and autoimmunity may involve bona fide immune tolerance
i.e an antigen-specific effect. Among the TLR agonists protective
for diabetes, it is interesting to highlight that the regulatory
mechanisms involved differed. Thus, TLR3 stimulation by
Poly(I:C) required the presence of NKT cells but not that of
CD4
+CD25
+FoxP3
+ T cells. Conversely, TLR4 stimulation by
LPS required the presence of CD4
+CD25
+FoxP3
+ T cells but not
that of NKT cells. It is also striking that diabetes protection by
TLR3 stimulation required the presence of IL-4 which was not the
case for TLR4-induced protection. It is to note that the role of
CD4
+CD25
+ T cells could not be tested in the allergic asthma
model since CD28
2/2 mice do not develop OVA-induced asthma
[43].
Finally, the role of cytokines is difficult to associate with a given
TLR since TLR-induced cytokine production, which was
consistently observed, varied with each agonist: one should note
however that TLR2, TLR3 and TLR7 agonists preferentially
stimulated IL-10 and TGF-b production which was not the case
Figure 8. Probiotic administration prevents from both allergic asthma and autoimmune diabetes: a TLR/MyD88 pathway-
dependent effect. A. NOD mice received 5 days a week for 6 weeks a preparation of probiotics (VSL#3, 5.10
9 bacteria/mouse) and underwent the
conventional OVA immunization/challenge protocol previously described. AHR as well as eosinophil counts in BALF and IL-4 levels in lung
homogenates were measured. Results showed that probiotic treatment significantly prevented from experimental allergic asthma (** p,0.01;
*** p,0.005). B. The same probiotic preparation (VSL#3; 5.10
9 bacteria/mouse) was administered orally by gavage to female NOD mice three times a
week starting at 4 weeks of age (n=8 per group). Results obtained demonstrated a very significant disease protection (*** p,0.005). C. In vitro
incubation for 24 hrs of peritoneal macrophages from NOD mice with increasing concentrations of the VSL#3 probiotic preparation induced a dose-
dependent production of TNF-a and IL-10. The MyD88 dependency of the effect was demonstrated by the lack of effect when macrophages from
MyD88
2/2 mice were analyzed. D. The probiotic-induced protection from allergic airway inflammation was MyD88-dependent as illustrated by the
comparative results obtained in MyD88
+/+ mice. The effect was illustrated here by the data on eosinophil counts in BALF showing that MyD88
2/2
mice (immunized and challenged according to the infraoptimal protocol, see figure 5) were completely refractory to the probiotic-treatment effect as
compared to MyD88
+/+ mice (** p,0.01). Results are representative of one experiment out of two.
doi:10.1371/journal.pone.0011484.g008
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PLoS ONE | www.plosone.org 11 July 2010 | Volume 5 | Issue 7 | e11484Figure 9. Probiotic treatment and immune regulation. A. The VSL#3 probiotic preparation was administered orally to female NOD mice 5
days a week for 2 weeks (n=5 per group). Twenty four hrs after the last administration sera were collected and circulating TGF-b was measured:
increased levels were found in mice treated with the active compound as compared to controls (* p,0.05). B. Mice underwent the conventional OVA
immunization/challenge protocol previously described and were treated prior to the first OVA challenge with either a neutralizing monoclonal
antibody to the IL-10R or an isotype-matched control. Results show that neutralization of IL-10 did not alter allergic inflammation (as assessed by
eosinophil recruitment in BALF and IL-4 production). One representative experiment out of two is shown. C. NOD mice received 5 days a week for 6
weeks either the VSL#3 probiotic preparation or PBS and then underwent the conventional OVA immunization/challenge protocol previously
described. Results obtained showed that the probiotic-protective effect was completely reversed (both in terms of reduction of AHR (** p,0.01) and
of eosinophil recruitment in BALF (* p,0.05, ** p,0.01)) following IL-10 neutralization upon administration of an anti-IL-10 receptor monoclonal
antibody prior to the first challenge. One representative experiment out of two is shown. D. Experimental allergic asthma was induced according to
the conventional OVA immunization/challenge protocol already described in normal NOD recipient mice transferred with CD4
+ cells purified from the
spleen of probiotic- or control-treated syngeneic mice. Purified CD4
+ cells were transferred 24 hrs before the first challenge. Results obtained showed
that both AHR and eosinophil recruitment in BALF were significantly decreased (** p,0.01 for both parameters) in recipients of CD4
+ cells recovered
from probiotic-treated donors. One representative experiment out of two is shown.
doi:10.1371/journal.pone.0011484.g009
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the complexity and the importance of TLR-mediated stimulation
of immunoregulatory cytokines as also recently shown by S.
Cohen et al. in experimental allergic encephalomyelitis [46].
In the context of this study we were faced with a dilemma
between attempting to reproduce ‘real life’, which means using
intact microorganisms or their extracts, or using a more reductionist
and contrived approach taking advantage of well defined
components of the microorganisms, such as the TLR ligands we
discussed, to get further insights into the fine cellular and molecular
mechanisms underlying the protective effects. Therefore, we
conducted the studies discussed above using well defined TLR
ligands in parallel to probiotics which we selected among
other microorganisms inasmuch as they have been shown to
have a significant therapeutic effect in clinical atopic dermatitis
[47–49].We provide evidence showing that probiotics function
through TLR stimulation as first, in vitro probiotics failed to induce
cytokine production by spleen cells from MyD88
2/2 NOD but not
from wild-typeNODmiceandsecond, they didprotectMyD88
2/2
NOD from allergic asthma in clear contrast with the significant
therapeutic effect observed in wild-type NOD mice. This model
allowed us to perform complementary mechanistic studies that
showed tranfer of protection by CD4
+ T cells, stimulation of IL-10
production and loss of the protective effect following administration
of a neutralizing anti-IL-10 receptor antibody.
The association of a defined mechanism with a specific TLR is
further complicated by the fact that for a given TLR distinct
agonists do not show the same pharmacological profile: for
instance in the case of TLR4, LPS is protective whereas lipid A is
not. In our initial screening of various TLR ligands it appeared
that lipid A, as compared to LPS, had a lower capacity to induce
cytokine production. This ‘lower’ stimulating capacity might be
the explanation for the lack of ‘therapeutic’ activity of this TLR4
ligand. In any event these data indicates that all ligands of a given
TLR do not have the same protective effect paving the way for an
immunopharmacology of each individual TLR ligand. Concern-
ing the molecular basis for these differential behavior, as
mentioned above, it has been well established that different
adaptor proteins i.e. MyD88 and TRIF mediate TLR4 signaling
[39]. One may speculate that signaling by given TLR4 ligands
may differentially involve these adaptors.
The whole of these data pave the way for a new pharmacology
of TLR stimulation in allergy and autoimmunity with contrasting
effects depending not only on the nature of the TLR receptor but
also on that of the specific ligand.
If it were confirmed that TLR stimulation modulates the
function of regulatory CD4
+CD25
+FoxP3
+ T cells or NKT cells, it
would be of central importance to determine whether this effect is
direct or indirect (e.g. through dendritic cells) [50,51]. Studies
from different laboratories indicate the presence of TLRs on
various subsets of regulatory T cells with however some
contradictory data [52–54]. One should also note that mecha-
nisms other that those discussed above could operate notably IL-
10 production by B cells [55–58]
The relevance of these results for the evolving epidemiology of
asthma and autoimmune type 1 diabetes is intriguing for the
search of new preventive treatments of these diseases. Results
presented in this manuscript indicate that TLR ligands present in
infectious agents could contribute to the protection afforded by
these agents against these diseases according to the hygiene
hypothesis. At the therapeutic level, our results suggest the
possibility of using TLR ligands or probiotics in the prevention
of allergic and autoimmune diseases inasmuch safety is fully
documented. The clinical relevance of the approach described is
based on the widely accepted concept that in the future major
breakthrough in the management of these diseases will come from
prevention rather than treatment of established disease. This
approach has already been implemented in atopic dermatitis,
using probiotics, and insulin-dependent type 1 diabetes in subjects
at risk of developing the disease (children with family history of
disease and, when available as in insulin-dependent diabetes
expressing at risk genetic alleles and/or autoantibody markers)
using candidate autoantigens in particular insulin delivered orally,
parenterally or intranasally [59,60]. In both situations these studies
involved long-term daily treatments (several months) as in our
present studies. It is important to mention with regard to our own
study that the promising but still to be confirmed encouraging
results obtained with probiotics in atopic dermatitis [47–49]. One
would certainly prefer, in the future, to use well-defined chemical
synthetic TLR agonists as those used in our work. Probiotics
present the interest of direct accessibility and low toxicity but suffer
from poor standardization. TLR agonists are probably more
potent but are confronted with the potential risk of stimulating
undesirable immune responses which would necessitate further
safety studies.
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